ClinicalTrials.gg
CompletedNCT01677858CHAMPION 1Updated Sep 23, 2022Results posted

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

A Phase 1/2 interventional study of Carfilzomib and Dexamethasone in Multiple Myeloma, sponsored by Amgen. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
25th of 113
116 · median 54
Started
2012
with 10 others
Phase 1/2
28 of 113
3 open now
Registered
30th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 25th largest by enrollment, is one of 11 that started in 2012, is one of 28 in phase 1/2, and was the 30th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The study had the following primary objectives:

  • Phase 1: to determine the maximum tolerated dose (MTD) of once-weekly (QW) carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior therapies
  • Phase 2: to estimate the overall response rate (ORR) for patients with relapsed or refractory multiple myeloma who received 1 to 3 prior therapies treated with carfilzomib and dexamethasone QW at the MTD established in phase 1.
Read the detailed description

This is a Phase 1/2, multicenter, single-arm, nonrandomized, open-label and dose-escalation study of weekly carfilzomib and dexamethasone for patients with progressive multiple myeloma. The Phase 1 dose escalation portion will enroll patients into sequential dose-escalating cohorts consisting of 3 patients each to establish the maximum tolerated dose (MTD) of carfilzomib administered weekly as a 30 minute intravenous (IV) infusion with dexamethasone. The Phase 2 portion will enroll patients using the MTD established for carfilzomib from the Phase 1 portion of the study. Dexamethasone will be administered IV or orally at the same dose and schedule as used in the Phase 1 portion of the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Multiple myeloma with relapsing or progressive disease at study entry
  2. , as defined by 1 or more of the following (assessed within 21 days prior to enrollment):

    1. Serum M-protein ≥ 0.5 g/dL, or
    2. Urine M-protein ≥ 200 mg/24 hours, or
    3. Only in patients who do not meet a or b, then use serum free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal kappa/lambda ratio
  3. Prior treatment with 1 to 3 prior regimens for multiple myeloma for Phase 1 and Phase 2 (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1
  4. Age ≥ 18 years
  5. ≥ 6 months
  6. (ECOG) performance status 0 or 1
  7. Adequate hepatic function within 21 days prior to enrollment, with \< 1.5 × the (ULN), and (AST) and alanine aminotransferase (ALT) \< 3 × ULN
  8. (LVEF) ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated acquisition scan (MUGA) is acceptable if ECHO is not available
  9. (ANC) ≥ 1000/mm³ within 21 days prior to enrollment. Screening ANC is to be independent of growth factor support for ≥ 1 week
  10. ≥ 8.0 g/dL within 21 days prior to enrollment. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed; however, most recent RBC transfusion must have been at least 7 days prior to obtaining screening hemoglobin
  11. count ≥ 50,000/mm³ (≥ 30,000/mm³ if myeloma involvement in the bone marrow is > 50%) within 21 days prior to enrollment. Patients must not have received platelet transfusions for at least 7 days prior to obtaining the screening platelet count
  12. Calculated or measured (CrCl) of ≥ 30 mL/min within 21 days prior to enrollment. Calculation based on standard formula, such as the Cockcroft and Gault: [(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)]; multiply result by 0.85 if female
  13. Written in accordance with federal, local, and institutional guidelines
  14. Female patients of (FCBP) must have a negative serum pregnancy test within 21 days prior to enrollment and agree to use an effective method of during and for 3 months following last dose of drug (more frequent pregnancy tests may be conducted if required per local regulations). females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from a pregnancy test
  15. Male patients must agree to use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with an FCBP

Exclusion criteria

Exclusion Criteria:

  1. Multiple myeloma of Immunoglobulin M (IgM) subtype
  2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  3. Plasma cell leukemia (> 2.0 × 10\^9/L circulating plasma cells by standard differential)
  4. Waldenström's macroglobulinemia
  5. Amyloidosis
  6. therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to enrollment
  7. Cytotoxic chemotherapy with approved or anticancer therapeutics within 28 days prior to enrollment
  8. Treatment with bortezomib (Velcade®), thalidomide (Thalomid®) or lenalidomide (Revlimid®) within 21 days prior to enrollment
  9. Focal radiation therapy within 7 days prior to enrollment. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment (ie, prior radiation must have been to \< 30% of the bone marrow)
  10. Immunotherapy within 21 days prior to enrollment
  11. Major surgery within 21 days prior to enrollment
  12. Active congestive heart failure ( [NYHA] Classes III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 6 months prior to enrollment
  13. Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at virus [HBV]), or antifungal agents within 14 days prior to enrollment
  14. Known (HIV) seropositivity
  15. Known hepatitis B or C virus infection (except for patients with HBV who are receiving and responding to HBV antiviral therapy: these patients are allowed)
  16. Patients with known cirrhosis
  17. Second within the past 3 years, except:

    1. Adequately treated basal cell or squamous cell skin cancer
    2. Carcinoma in situ of the cervix
    3. Prostate cancer \< Gleason score 6 with stable prostate-specific antigen (PSA) over 12 months
    4. Breast carcinoma in situ with full surgical resection
    5. Treated medullary or papillary thyroid cancer
  18. Patients with myelodysplastic syndrome
  19. Significant neuropathy (Grades 3 to 4) within 14 days prior to enrollment
  20. Female patients who are pregnant or lactating
  21. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  22. Prior carfilzomib treatment
  23. Prior participation in any Onyx-sponsored Phase 3 trial
  24. Patients with to dexamethasone
  25. Contraindication to any of the required concomitant drugs or supportive treatments, including to antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
  26. Ongoing
  27. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment
  28. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
  29. Any other medical disease or psychiatric condition that, in the Investigator's opinion, may interfere with protocol adherence or a patient's ability to give
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Carfilzomib

    In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15. In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study. Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study.

    Drug: Carfilzomib · Drug: Dexamethasone

Interventions

  • Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.

    Also known as: Krypolis

  • Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)

    The MTD was defined as the highest carfilzomib dose at which \< 33% of participants had a treatment-related DLT during the first 28-day cycle. A DLT was categorized as nonhematologic or hematologic and defined as follows: Nonhematologic: * ≥ grade 3 nonhematological toxicity (excluding nausea, vomiting, diarrhea, fatigue lasting \< 14 days, increased serum creatinine or electrolyte abnormalities not clinically significant or requiring treatment) * ≥ grade 3 acute kidney injury (creatinine \> 3 x baseline or \> 4.0 mg/dL) lasting \> 72 hours * ≥ grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) for \> 7 days * febrile neutropenia (ANC \< 1000/mm³ with a fever ≥ 38.3ºC) of any duration * grade 4 thrombocytopenia (\< 25 000/mm³) for \> 14 days, despite holding treatment * grade 3 or 4 thrombocytopenia (\< lower limit of normal) associated with \> grade 1 bleeding

    Time frame: 28 days

  2. Overall Response Rate (ORR)

    Disease response was evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). ORR was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

    Time frame: Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.

Secondary outcomes

  1. Clinical Benefit Response Rate

    Clinical benefit rate was defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a 25% to 49% reduction in the level of serum M-protein or a 50% to 89% reduction in 24-hour urinary M-protein, which still exceeds 200 mg /24 hour, maintained for a minimum of 8 weeks.

    Time frame: Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.

  2. Progression-free Survival

    Progression-free survival (PFS) was defined as the time from first dose to the earlier of disease progression or death due to any cause. The duration of PFS was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored. Participants were evaluated for disease response and progression by the investigator according to the IMWG-URC.

    Time frame: From randomization until the data cut-off date of 22 July 2016; median follow-up time for PFS was 13.8 months

  3. Time To Progression

    Time to progression (TTP) was defined as the time from first dose to disease progression evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). TTP was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored.

    Time frame: From randomization until the data cut-off date of 22 July 2016; median follow-up time for TTP was 13.4 months

  4. Duration of Response

    Duration of response (DOR) was defined as the time from first evidence of PR or better to disease progression or death due to any cause. DOR was calculated using Kaplan-Meier methods; Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.

    Time frame: From randomization until the data cut-off date of 22 July 2016; median follow-up time for DOR was 14.3 months

  5. Number of Participants With Adverse Events

    Adverse events were graded using National Cancer Institute-Common Terminology Criteria for Adverse Events (version 4.03).

    Time frame: From the first day of study treatment and within 30 days of the last day of study treatment; median duration of treatment was 33.6 weeks.

  6. Time to Maximum Plasma Concentration of Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  7. Maximum Plasma Concentration of Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  8. Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  9. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  10. Area Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  11. Volume of Distribution Observed at Steady State (Vss) for Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  12. Terminal Half-life (T1/2,z) for Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  13. Clearance of Carfilzomib After IV Infusion

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

  14. Mean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib

    Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.

07

Results

Posted Aug 9, 2017

Participant flow

This study was conducted at 32 centers in the United States. Participants were enrolled from September 2012 to September 2014.

Participant flow — Overall Study
MilestonePhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²
Started3315689
Completed01104
Not completed3214685
Withdrew: Adverse event002313
Withdrew: Death00001
Withdrew: Physician decision102012
Withdrew: Progressive disease219343
Withdrew: Withdrawal by subject011015
Withdrew: Lost to follow-up00001

Outcome measures

PrimaryPhase 1: Number of Participants With Dose-limiting Toxicities (DLTs)

The MTD was defined as the highest carfilzomib dose at which \< 33% of participants had a treatment-related DLT during the first 28-day cycle. A DLT was categorized as nonhematologic or hematologic and defined as follows: Nonhematologic: * ≥ grade 3 nonhematological toxicity (excluding nausea, vomiting, diarrhea, fatigue lasting \< 14 days, increased serum creatinine or electrolyte abnormalities not clinically significant or requiring treatment) * ≥ grade 3 acute kidney injury (creatinine \> 3 x baseline or \> 4.0 mg/dL) lasting \> 72 hours * ≥ grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) for \> 7 days * febrile neutropenia (ANC \< 1000/mm³ with a fever ≥ 38.3ºC) of any duration * grade 4 thrombocytopenia (\< 25 000/mm³) for \> 14 days, despite holding treatment * grade 3 or 4 thrombocytopenia (\< lower limit of normal) associated with \> grade 1 bleeding

Time frame:
28 days
Reported as:
Number · participants
Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)
participantsPhase 1 Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²
Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)0012
Statistical analysis
  • Phase 1 Carfilzomib 45 mg/m² vs Phase 1: Carfilzomib 56 mg/m² vs Phase 1: Carfilzomib 70 mg/m² vs Phase 1: Carfilzomib 88 mg/m² · Maximum tolerated dose (mg/m²): 70
PrimaryOverall Response Rate (ORR)

Disease response was evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). ORR was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.

Time frame:
Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Phase 1+2: Carfilzomib 70 mg/m²
Overall Response Rate (ORR)33.3 (0.8 to 90.6)100 (29.2 to 100.0)93.3 (68.1 to 99.8)66.7 (22.3 to 95.7)74.2 (63.8 to 82.9)76.9 (67.6 to 84.6)
SecondaryClinical Benefit Response Rate

Clinical benefit rate was defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a 25% to 49% reduction in the level of serum M-protein or a 50% to 89% reduction in 24-hour urinary M-protein, which still exceeds 200 mg /24 hour, maintained for a minimum of 8 weeks.

Time frame:
Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.
Reported as:
Number · percentage of participants
Clinical Benefit Response Rate
percentage of participantsPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Phase 1+2: Carfilzomib 70 mg/m²
Clinical Benefit Response Rate66.7 (9.4 to 99.2)100.0 (29.2 to 100.0)100.0 (78.2 to 100.0)83.3 (35.9 to 99.6)80.9 (71.2 to 88.5)83.7 (75.1 to 90.2)
SecondaryProgression-free Survival

Progression-free survival (PFS) was defined as the time from first dose to the earlier of disease progression or death due to any cause. The duration of PFS was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored. Participants were evaluated for disease response and progression by the investigator according to the IMWG-URC.

Time frame:
From randomization until the data cut-off date of 22 July 2016; median follow-up time for PFS was 13.8 months
Reported as:
Median · months
Progression-free Survival
monthsPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Phase 1+2: Carfilzomib 70 mg/m²
Progression-free Survival13.6 (6.4 to 20.7)NA (41.7 to NA)21.0 (4.2 to NA)12.9 (3.9 to 20.0)15.3 (10.0 to 20.2)16.2 (10.2 to 21.0)
SecondaryTime To Progression

Time to progression (TTP) was defined as the time from first dose to disease progression evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). TTP was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored.

Time frame:
From randomization until the data cut-off date of 22 July 2016; median follow-up time for TTP was 13.4 months
Reported as:
Median · months
Time To Progression
monthsPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Phase 1+2: Carfilzomib 70 mg/m²
Time To Progression13.6 (6.4 to 20.7)NA (41.7 to NA)21.0 (4.2 to NA)12.9 (3.9 to 20.0)16.2 (10.2 to 20.2)17.2 (10.6 to 21.7)
SecondaryDuration of Response

Duration of response (DOR) was defined as the time from first evidence of PR or better to disease progression or death due to any cause. DOR was calculated using Kaplan-Meier methods; Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.

Time frame:
From randomization until the data cut-off date of 22 July 2016; median follow-up time for DOR was 14.3 months
Reported as:
Median · months
Duration of Response
monthsPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Phase 1+2: Carfilzomib 70 mg/m²
Duration of Response18.9 (NA to NA)NA (39.9 to NA)16.3 (3.3 to NA)11.9 (11.1 to 18.9)18.0 (13.7 to 21.9)18.0 (14.5 to 21.9)
SecondaryNumber of Participants With Adverse Events

Adverse events were graded using National Cancer Institute-Common Terminology Criteria for Adverse Events (version 4.03).

Time frame:
From the first day of study treatment and within 30 days of the last day of study treatment; median duration of treatment was 33.6 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²
All adverse events3315689
Adverse events ≥ grade 3129560
Serious adverse events104135
AE leading to discontinuation of carfilzomib & dex002314
AE leading to discontinuation of carfilzomib002314
Fatal adverse events00005
SecondaryTime to Maximum Plasma Concentration of Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Plasma Concentration of Carfilzomib
hoursCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Time to Maximum Plasma Concentration of Carfilzomib0.25 (0.17 to 0.75)0.25 (0.08 to 0.58)0.25 (0.25 to 0.58)
SecondaryMaximum Plasma Concentration of Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration of Carfilzomib
ng/mLCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Maximum Plasma Concentration of Carfilzomib789 ± 65.52390 ± 30.73090 ± 27.3
SecondaryArea Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib
hr*ng/mLCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib281 ± 52.71040 ± 21.71210 ± 31.4
SecondaryArea Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib
hr*ng/mLCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib259 ± 28.01040 ± 21.61160 ± 34.8
SecondaryArea Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib
hr*ng/mLCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Area Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib259 ± 28.01040 ± 21.61160 ± 34.8
SecondaryVolume of Distribution Observed at Steady State (Vss) for Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters
Volume of Distribution Observed at Steady State (Vss) for Carfilzomib
litersCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Volume of Distribution Observed at Steady State (Vss) for Carfilzomib17.0 ± 133.314.2 ± 54.27.87 ± 78.4
SecondaryTerminal Half-life (T1/2,z) for Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Terminal Half-life (T1/2,z) for Carfilzomib
hoursCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Terminal Half-life (T1/2,z) for Carfilzomib0.648 ± 490.883 ± 24.60.816 ± 17.1
SecondaryClearance of Carfilzomib After IV Infusion
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters/hour
Clearance of Carfilzomib After IV Infusion
liters/hourCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Clearance of Carfilzomib After IV Infusion147 ± 31.0131 ± 29.6138 ± 35.0
SecondaryMean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib
Time frame:
Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib
hoursCarfilzomib 20 mg/m²Carfilzomib 70 mg/m²Carfilzomib 88 mg/m²
Mean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib0.118 ± 130.50.108 ± 55.40.0571 ± 110.0

Adverse events

Collected over From the first day of study treatment and within 30 days of the last day of study treatment; median duration of treatment was 33.6 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Carfilzomib 45 mg/m²—1/3 (33.3%)3/3 (100%)
Phase 1: Carfilzomib 56 mg/m²—0/3 (0%)3/3 (100%)
Phase 1: Carfilzomib 70 mg/m²—4/15 (26.7%)15/15 (100%)
Phase 1: Carfilzomib 88 mg/m²—1/6 (16.7%)6/6 (100%)
Phase 2: Carfilzomib 70 mg/m²—35/89 (39.3%)87/89 (97.8%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²
Blood creatinine increasedInvestigations1/30/30/150/60/89
HyponatraemiaMetabolism and nutrition disorders1/30/30/150/60/89
Cardiac failure congestiveCardiac disorders0/30/30/151/62/89
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/30/32/150/63/89
Acute kidney injuryRenal and urinary disorders0/30/31/150/66/89
PneumoniaInfections and infestations0/30/31/150/64/89
SepsisInfections and infestations0/30/31/150/65/89
Urinary tract infectionInfections and infestations0/30/31/150/61/89
EncephalopathyNervous system disorders0/30/31/150/60/89
ThrombocytopeniaBlood and lymphatic system disorders0/30/30/150/62/89
Most frequent other events
Showing 10 of 212
Most frequent other events
EventPhase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²
FatigueGeneral disorders3/32/39/153/647/89
Upper respiratory tract infectionInfections and infestations1/32/312/152/625/89
AnaemiaBlood and lymphatic system disorders1/32/35/151/625/89
Vision blurredEye disorders0/32/31/152/65/89
DiarrhoeaGastrointestinal disorders2/30/39/152/626/89
Cardiac murmurInvestigations0/32/30/150/62/89
ArthralgiaMusculoskeletal and connective tissue disorders0/32/35/150/615/89
Back painMusculoskeletal and connective tissue disorders2/30/35/151/618/89
OsteoarthritisMusculoskeletal and connective tissue disorders0/32/30/150/60/89
HeadacheNervous system disorders0/32/36/154/626/89

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Total
Mean69.3 ± 15.673.7 ± 2.162.4 ± 10.458.2 ± 8.868.7 ± 9.667.5 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Total
Female12454052
Male211114964
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Total
Hispanic or Latino00011011
Not Hispanic or Latino3315579105
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Total
White3211679101
Black or African American012069
Asian000011
American Indian or Alaskan Native000000
Native Hawaiian or Other Pacific Islander000011
Other002013
Unknown000011
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Phase 1: Carfilzomib 45 mg/m²Phase 1: Carfilzomib 56 mg/m²Phase 1: Carfilzomib 70 mg/m²Phase 1: Carfilzomib 88 mg/m²Phase 2: Carfilzomib 70 mg/m²Total
0 (Fully active)12633951
1 (Restrictive but ambulatory)21935065
08

Study locations

35 sites
  • Arizona Oncology Associates
    Tucson, Arizona, United States
  • Comprehensive Blood and Cancer Center (CCBC)
    Bakersfield, California, United States
  • California Cancer Associates for Research and Excellence
    Encinitas, California, United States
  • Robert A. Moss, M.D., FACP, Inc.
    Fountain Valley, California, United States
  • California Cancer Associates for Research and Excellence
    Fresno, California, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California, United States
  • Monterey Bay Oncology
    Salinas, California, United States
  • Sansum Clinic
    Santa Barbara, California, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California, United States
  • James R. Berenson M.D. Inc.
    West Hollywood, California, United States
  • The Oncology Insititute of Hope and Innovation
    Whittier, California, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado, United States
  • Florida Cancer Specialists - South
    Fort Myers, Florida, United States
  • Florida Cancer Specialists - North
    Tampa, Florida, United States
  • Illinois Cancer Care
    Galesburg, Illinois, United States
  • Illinois Cancer Specialists
    Hinsdale, Illinois, United States
  • Illinois Cancer Specialists
    Niles, Illinois, United States
  • Fort Wayne Oncology & Hematology
    Fort Wayne, Indiana, United States
  • Horizon Oncology Research, Inc.
    Lafayette, Indiana, United States
  • Center for Cancer and Blood Disorders (CCBD)
    Bethesda, Maryland, United States
  • Hematology-Oncology Associates of Northern NJ, PA
    Morristown, New Jersey, United States
  • New Mexico Cancer Care Alliance
    Albuquerque, New Mexico, United States
  • Clinical Research Alliance
    New York, New York, United States
  • Hudson Valley Hematology Oncology Associates
    Poughkeepsie, New York, United States
  • Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon, United States
  • Tennessee Oncology, PLLC
    Chattanooga, Tennessee, United States
  • St. Joseph Regional Cancer Center
    Bryan, Texas, United States
  • Millennium Oncology
    Houston, Texas, United States
  • Waldron Medical Research and Development Center
    Houston, Texas, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas, United States
  • Center at Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio
    San Antonio, Texas, United States
  • Blood and Cancer Center of East Texas
    Tyler, Texas, United States
  • Shenandoah Oncology, PC
    Winchester, Virginia, United States
  • Northwest Cancer Specialists
    Vancouver, Washington, United States
  • Yakima Valley Memorial Hospital/ North Star Lodge
    Yakima, Washington, United States
09

References and documents

Publications

  • Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, Mateos MV. Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med. 2020 May;9(9):2989-2996. doi: 10.1002/cam4.2945. Epub 2020 Feb 28. PubMed 32108443 ↗
  • Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12. PubMed 27207788 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jul 2016 and a completion of Oct 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2012
First posted
Sep 3, 2012
Start
Jul 4, 2012
Primary completionActual
Jul 22, 2016
CompletionActual
Oct 31, 2018
Results first posted
Aug 9, 2017
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01677858
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 3, 2012
Start date
Jul 4, 2012
Primary completion
Jul 22, 2016
Completion
Oct 31, 2018
Results posted
Aug 9, 2017
Last update
Sep 23, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion